Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603407 | 0.80 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL14417816 | 0.79 | POLB (0.38) | HSD17B10ALDH1A1TSHRALOX15MAPK1 | |
| SCHEMBL18155849 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL25908413 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL25723117 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL17970231 | 0.76 | ALDH1A1 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL23345002 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL5217778 | 0.76 | HRH3 (0.35) | CYP2D6SMN1; SMN2CYP2C19 | |
| SCHEMBL23995668 | 0.76 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL27561659 | 0.76 | NEK2 (0.43) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-17 | — | — | US | disclosed |
| WO-2023150612-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3302549-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016188935-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | CYP2D6 954/4885SMN1; SMN2 2109/4885NEK2 1006/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | CYP2D6 2078/4885SMN1; SMN2 2342/4885NEK2 870/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP2D6 1282/4885SMN1; SMN2 432/4885NEK2 1284/4885 |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CYP2D6 618/4885SMN1; SMN2 1955/4885NEK2 138/4885 |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | BCL2L1, MCL1, CD22 | CYP2D6 2290/4885SMN1; SMN2 4074/4885NEK2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.